The purpose of this study is to see if guselkumab and golimumab when used together is safe and effective for treating participants with moderately to severely active ulcerative colitis (UC).
Guselkumab has been approved in the USA, the European Union (EU), Canada, and several other countries, including the Australian health authority (Therapeutic Goods Administration), for the treatment of adult patients with moderate to severe plaque psoriasis. In addition, guselkumab is being studied for the treatment of psoriatic arthritis, Crohn’s disease, and paediatric psoriasis.
Golimumab has been approved in countries worldwide, including the Therepeutic Goods Administration, for the indications of moderately to severely active ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
The main purpose of this study is to find out whether the study drug Pexa-Vec followed by standard Sorafenib treatment is better at treating your cancer than standard Sorafenib treatment alone.
Pexa-Vec is a virus that has been altered in a laboratory (genetically modified) to infect and destroy cancer cells and release a protein called GM-CSF that plays a role in the defense system fighting cancer.
The primary purpose of your participation in this study is not to treat you for your condition but to help answer the following research question: How mirikizumab compares with placebo in helping patients with UC?
Mirikizumab is an experimental treatment. This means that it is not an approved treatment for UC in Australia, by the Therapeutic Goods Administration.
The ColoSTAT® test is being developed to provide an alternative option for people to undergo a colorectal cancer (CRC) screening test but for clinical, personal or cultural reasons, are unwilling or unable to use a stool test or are reluctant to undergo more invasive and costly procedures such as colonoscopy and sigmoidoscopy.
ColoSTAT® involves the collection of a blood sample, rather than stool, to assess the presence of components in the blood which, when assessed using a specifically designed algorithm, provide a CRC risk score. The algorithm uses the results from the blood test and incorporates other CRC risk factors, such as family history and lifestyle factors to determine this risk rating.
The purpose of this study is to assess a novel blood collection device, called a Plasma Separation Device (PSD), which has been developed at the Burnet Institute in Melbourne. The PSD is designed to collect and store blood samples in remote and resource-poor settings and to assist with infectious diseases testing. The study team want to measure the effectiveness of the PSD for the diagnosis of Hepatitis B, Hepatitis C and HIV. They also want to see if the PSD can detect other immune responses to infectious diseases that you have been vaccinated against (e.g. measles or tetanus).
The purpose of this research is to find out whether the study medication denosumab can help prevent breast cancer in women with a BRCA1 mutation. The research also aims to find out whether denosumab decreases the risk of developing ovarian cancer or other types of cancer, study the safety of using denosumab, and study its effect on bone health.
The study is a randomised, double-blind, placebo-controlled study. This means that participants will receive an injection of either denosumab or placebo (no drug) every 6 months for 5 years. Participants will need to visit their study doctor every 6 months while receiving the medication and will continue to be checked by their study team every 12 months for a further 5 years (total of 10 years).
SKY-D is investigating whether ketamine is an effective treatment for young people with depression.
We are inviting young people aged 16 to 25 years, with moderate-to-severe depression, to take part in this research. Participants will divided into two groups. One group will receive a low dose of ketamine once a week for four weeks. The other group will receive a low dose of another medication, called midazolam, once a week for four weeks.
We hope that the results of this study will help us to provide the best possible care in the future for young people with depression.
Patients diagnosed with glioblastoma are treated with a combination of chemotherapy and radiation, followed by six months of temozolomide (chemotherapy). However, even with the best treatment, the average survival is around 14 months. Previous research has suggested that an extra six months of temozolomide may improve survival without any impact on quality of life or symptoms related to treatment. However, these studies were small and unable to provide a definitive answer. In some centres, it is standard to use six months of chemotherapy, whilst in others, the standard is 12 months.
The purpose of this study is to determine if an additional six months of temozolomide will improve the survival of patients with glioblastoma. We will also assess whether an additional six months of temozolomide causes more side effects.
Patients who decide to participate in the trial will be randomly assigned to either receive an additional six months of temozolomide chemotherapy or not and continue with their usual care.